InvestSMART

Recce Pharmaceuticals Ltd (ASX:RCE)

ALERT: Price-sensitive ASX Announcement for RCE
Current share price for RCE : $0.385 -0.005 (-1.28%)+
Announcement
Release
14 Jul 2026 8:56AM
Price at Release
$0.390
Full Release
download
Summary
Recce Pharmaceuticals Ltd, an Australian-based company, has announced the granting of a Family 4 patent by the Intellectual Property Office of Vietnam for their synthetic anti-infectives, RECCE® 327 and RECCE® 529. These anti-infectives are designed to treat bacterial and viral infections and are significant in combating antibiotic-resistant superbugs. The patent covers the preparation process and various administration methods of RECCE® anti-infectives, including oral and injectable forms. The Vietnamese patent adds to Recce's global intellectual property portfolio, strengthening its presence in Southeast Asia, a region facing significant antimicrobial resistance challenges. Recce aims to leverage this patent to advance and commercialize its anti-infective platform, addressing urgent global health issues.
Key Points
  • Vietnamese patent granted for Recce's anti-infectives.
  • Patent covers RECCE® 327 and RECCE® 529.
  • Significant for treating antibiotic-resistant superbugs.
  • Includes various administration methods.
  • Strengthens Recce's global IP portfolio.
  • Vietnam faces high rates of antibiotic resistance.
  • Supports Recce's strategy to combat global health challenges.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.